French Guiana Wellness Network: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Guiana Wellness Network.

Press releases published on September 2, 2026

Sep. 2, 2026

Next Generation Sequencing Market to reach USD 42.61 Billion by 2035 at 14.7% CAGR

Indeterminate EIN Presswire

Sep. 2, 2026

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 2, 2026

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 2, 2026

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 2, 2026

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 2, 2026

Supernus Pharmaceuticals to Participate in September Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Vireo Growth Announces Conference Attendance for September 2026

Indeterminate GlobeNewswire

Sep. 2, 2026

Flyte Secures International Approval to Launch Private Aviation Service Across The Bahamas and Caribbean

Indeterminate GlobeNewswire

Sep. 2, 2026

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

Indeterminate GlobeNewswire

Sep. 2, 2026

AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference

Indeterminate GlobeNewswire

Sep. 2, 2026

Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients

Indeterminate GlobeNewswire

Sep. 2, 2026

Nyxoah Annonce que l'Étude Pivot Américaine ACCCESS Atteint ses Critères Principaux de Sécurité et d'Efficacité chez les Patients Présentant un Collapsus Concentrique Complet

Indeterminate GlobeNewswire

Sep. 2, 2026

Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH

Indeterminate GlobeNewswire

Sep. 2, 2026

Inventiva annonce la dernière visite du dernier patient de l’étude clinique de Phase 3 NATiV3 évaluant le lanifibranor dans la MASH

Indeterminate GlobeNewswire

Sep. 2, 2026

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Sep. 2, 2026

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Option Care Health to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Surrozen to Present at Upcoming Healthcare Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Kyverna Therapeutics to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire

Sep. 2, 2026

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

Indeterminate GlobeNewswire